Esperion Therapeutics' (ESPR) LDL-Lowering Drug Supported by KOLs - Citizens
Tweet Send to a Friend
Citizens analyst Jason N. Butler reiterated a Market Outperform rating and $4.00 price target on Esperion Therapeutics (NASDAQ: ESPR).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
